2003至2022年间意大利新生儿糖尿病格局的变化
该研究比较了意大利2003-2012年(Sanger测序)与2013-2022年(二代测序)新生儿糖尿病(NDM)和先天性严重胰岛素抵抗(c.SIR)患者的遗传分析结果。共纳入104例6月龄前发病患者,20年NDM发病率为1:103340活产,c.SIR为1:1240082活产;二代测序使罕见基因变异检出率从2.4%升至19%(P=0.034),并促成精准治疗。
要点
- 二代测序使罕见基因变异检出率由2003-2012年的2.4%升至2013-2022年的19%(P=0.034)。
- 自身免疫性NDM(FOXP3、IL2RA、LRBA)患者接受了骨髓移植。
- 胰腺发育不全/发育不良(RFX6、PDX1)患者补充胰酶,BSCL2所致脂肪营养不良者起始美曲普汀治疗。
核心结论
- 二代测序显著改善了意大利单基因新生儿糖尿病和先天性严重胰岛素抵抗的诊断与精准治疗。
研究设计与样本
- 回顾性分析意大利数据集104例6月龄前发病的糖尿病和先天性严重胰岛素抵抗患者的临床与遗传记录,比较2003-2012年(Sanger测序)与2013-2022年(二代测序)两个时段。
主要发现
- 2003-2012年识别55例(50例NDM+5例c.SIR),2013-2022年识别49例(46例NDM+3例c.SIR)。
- 20年NDM发病率为1:103340活产,c.SIR发病率为1:1240082活产。
- 常见NDM/c.SIR遗传缺陷(KCNJ11、INS、ABCC8、6q24、INSR)在2003-2012年和2013-2022年分别检出41例和34例先证者。
- 罕见基因致病性变异在2003-2012年检出1例先证者(GATA4,1/42即2.4%),在2013-2022年检出8例婴儿(RFX6、PDX1、GATA6、HNF1B、FOXP3、IL2RA、LRBA、BSCL2,8/42即19%,P=0.034 vs 2003-2012年)。
- 罕见基因中5个为隐性遗传。
临床怎么用
- 自身免疫性NDM(FOXP3、IL2RA、LRBA)患者接受了骨髓移植。
- 胰腺发育不全/发育不良(RFX6、PDX1)患者补充了胰酶。
- BSCL2所致脂肪营养不良的个体起始了美曲普汀治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In the last decade the Sanger method of DNA sequencing has been replaced by next-generation sequencing (NGS). NGS is valuable in conditions characterized by high genetic heterogeneity such as neonatal diabetes mellitus (NDM). OBJECTIVE: To compare results of genetic analysis of patients with NDM and congenital severe insulin resistance (c.SIR) identified in Italy in 2003-2012 (Sanger) vs 2013-2022 (NGS). METHODS: We reviewed clinical and genetic records of 104 cases with diabetes onset before 6 months of age (NDM + c.SIR) of the Italian dataset. RESULTS: Fifty-five patients (50 NDM + 5 c.SIR) were identified during 2003-2012 and 49 (46 NDM + 3 c.SIR) in 2013-2022. Twenty-year incidence was 1:103 340 (NDM) and 1:1 240 082 (c.SIR) live births. Frequent NDM/c.SIR genetic defects (KCNJ11, INS, ABCC8, 6q24, INSR) were detected in 41 and 34 probands during 2003-2012 and 2013-2022, respectively. We identified a pathogenic variant in rare genes in a single proband (GATA4) (1/42 or 2.4%) during 2003-2012 and in 8 infants (RFX6, PDX1, GATA6, HNF1B, FOXP3, IL2RA, LRBA, BSCL2) during 2013-2022 (8/42 or 19%, P = .034 vs 2003-2012). Notably, among rare genes 5 were recessive. Swift and accurate genetic diagnosis led to appropriate treatment: patients with autoimmune NDM (FOXP3, IL2RA, LRBA) were subjected to bone marrow transplant; patients with pancreas agenesis/hypoplasia (RFX6, PDX1) were supplemented with pancreatic enzymes, and the individual with lipodystrophy caused by BSCL2 was started on metreleptin. CONCLUSION: NGS substantially improved diagnosis and precision therapy of monogenic forms of neonatal diabetes and c.SIR in Italy.
引用
- Rapini N, Delvecchio M, Mucciolo M, et al. The Changing Landscape of Neonatal Diabetes Mellitus in Italy Between 2003 and 2022. J Clin Endocrinol Metab. 2024. PMID: 38408297. doi:10.1210/clinem/dgae095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。